Akebia Therapeutics (AKBA) Reports In-Line Q3 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $40.12 million versus the consensus estimate of $49.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand